MedTrace Logo

Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)

NCT06145100 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-05-01

No results posted yet for this study

Summary

Patients with CVID will be offered to participate in this observational trial during the routine annual visit in the outpatient clinic at the Center of chronic Immunodeficiency (CCI) of the University Medical Center Freiburg, Germany.

Clinical and laboratory data at the time of presentation will be assessed. Additionally, parameters of abdominal ultrasound, duplex sonography of the liver and spleen, and liver and spleen stiffness at the time of presentation will be evaluated. If applicable, clinical and/or interventional parameters indicating clinically significant portal hypertension (i.e. presence of varices or portal-hypertensive gastropathy in esophago-gastroduodenoscopy, presence of ascites) within 12 months prior and after the index visit will be assessed. During the visit, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in an associated biobank.

Conditions

  • Non-Cirrhotic Portal Hypertension
  • Common Variable Immunodeficiency

Interventions

DIAGNOSTIC_TEST

Ultrasound including color doppler ultrasound

Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.

Sponsors & Collaborators

  • University Hospital Freiburg

    lead OTHER

Principal Investigators

  • Dominik Bettinger, MD · University Hospital Freiburg

  • Klaus Warnatz, MD · University Hospital Freiburg

  • Marlene Reincke, MD · University Hospital Freiburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-12-31
Completion
2026-03-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06145100 on ClinicalTrials.gov